Labcorp stock (US50540R4092): Modest move as institutional investors add exposure

Labcorp shares on the NYSE were little changed on Monday, while fresh 13F filings show additional institutional buying in the United States, keeping attention on the diagnostics provider’s positioning in the healthcare sector.

Labcorp shares traded largely flat in the United States on Monday, with the stock around USD 260 on the New York Stock Exchange as institutional ownership data for the fourth quarter highlighted further buying by large investors, underlining continued interest in the diagnostics and clinical laboratory group according to MarketBeat as of 06/01/2026.

Recent 13F disclosures show that the National Pension Service increased its stake in Labcorp by 3.8% in the fourth quarter, purchasing 6,251 additional shares, while Eurizon Capital SGR S.p.A. initiated or expanded a position valued at about USD 17.36 million over the same period, based on MarketBeat filings reported on 06/01/2026.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Labcorp
• Sector/industry: Diagnostics and medical laboratory services
• Headquarters/country: Burlington, United States
• Core markets: United States with services offered internationally
• Key revenue drivers: Routine and specialty diagnostic testing, clinical trial services, and related laboratory solutions
• Home exchange/listing venue: New York Stock Exchange (LH)
• Trading currency: USD

Labcorp: core business model

Labcorp primarily operates as a large-scale diagnostics and clinical laboratory services provider, generating the bulk of its revenue from processing routine and specialized tests for healthcare providers, hospitals, and biopharmaceutical clients while also supporting drug development through its clinical trial solutions.

What banks and research houses say about Labcorp

According to MarketBeat data cited on 06/01/2026, Labcorp currently holds a consensus rating of "Moderate Buy" from covering analysts, with an average price target of USD 308.00, indicating that research houses broadly view the stock positively over their respective horizons.

The same MarketBeat overview notes that this consensus target sits well above where Labcorp opened at USD 260.21 on Monday, 06/01/2026, offering investors a snapshot of how the sell-side community balances the company’s diagnostics and clinical trial exposure with broader healthcare sector dynamics in the United States.

Conclusion

Labcorp’s largely unchanged share price on the NYSE on Monday comes against a backdrop of incremental institutional buying, underscored by fourth-quarter filings from the National Pension Service and Eurizon Capital SGR S.p.A., which point to sustained interest from long-term investors.

At the same time, the prevailing "Moderate Buy" consensus rating and average price target of USD 308.00 compiled by MarketBeat highlight how banks and research houses currently assess the company’s diagnostics and clinical trial businesses within the broader U.S. healthcare landscape.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.